Macomics expands drug discovery R & D team
Macomics, an immuno-oncology company with world-leading expertise in macrophage biology, has made five new appointments to its scientific teams in Cambridge and Edinburgh to support and accelerate its R & D.
Moritz Haneklaus joins as senior scientist, Carmen Rodriguez Seoane as scientist, with Chantell Payton and Conor Poland coming on board as associate scientists, and Sadie Kemp as senior research technician.
Moritz will be based in Cambridge and utilise his deep immunology expertise to support progression of the company’s discovery portfolio and development of novel cell-based assays.
He brings 10 years molecular immunology experience to the company with international experience gained in the UK, Ireland, Sweden and Germany.
Carmen, Conor, and Sadie will be based at Macomics’ Edinburgh site and Chantell at the Cambridge site.
This expansion follows Macomics’ follow-on financing of £4.24 million announced in July.
The company is developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic.